A Phase I dose-ranging study to investigate the safety, tolerability and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous, and intravenous administration in subjects with various lymphomas and leukemias

UCI-16-46
NCT02580552
Cancer - Mycosis Fungoides, Cancer - Non-Hodgkin's Lymphoma
Lauren C Pinter-Brown
Open
Treatment
MRG-106
I
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.